What is the current state of thrombosis treatment and prevention in cancer patients?

J Med Vasc. 2020 Nov;45(6S):6S1-6S2. doi: 10.1016/S2542-4513(20)30512-5.

Author

D Farge¹

Affiliation

¹ Internal Medicine, Autoimmune and Vascular Disease Unit, Saint-Louis Hospital, Assistance Publique Hôpitaux de Paris, Université de Paris, Paris, France; Groupe Francophone Thrombose et Cancer, Paris, France; McGill University, Montreal, Québec, Canada. Electronic address: dominique.farge-bancel@aphp.fr.

PMID: 33276938
DOI: 10.1016/S2542-4513(20)30512-5

No abstract available

Publication types

Editorial
Introductory Journal Article

MeSH terms

Administration, Oral
Anticoagulants / administration & dosage*
Anticoagulants / adverse effects
Factor Xa Inhibitors / administration & dosage
Fibrinolytic Agents / administration & dosage*
Fibrinolytic Agents / adverse effects
Humans
Neoplasms / diagnosis
Neoplasms / drug therapy*
Neoplasms / epidemiology
Risk Factors
Treatment Outcome
Venous Thromboembolism / diagnosis
Venous Thromboembolism / drug therapy*
Venous Thromboembolism / epidemiology
Venous Thromboembolism / prevention & control*

Substances

Anticoagulants
Factor Xa Inhibitors
Fibrinolytic Agents